11/22
01:51 pm
hrow
OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case
Low
Report
OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case
11/21
07:00 am
hrow
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
Medium
Report
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
11/20
07:00 am
hrow
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Medium
Report
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
11/15
07:00 am
hrow
Harrow Announces Participation in Upcoming Investor Conferences
Medium
Report
Harrow Announces Participation in Upcoming Investor Conferences
11/13
04:34 pm
hrow
Harrow Announces Third Quarter 2024 Financial Results
High
Report
Harrow Announces Third Quarter 2024 Financial Results
11/13
07:00 am
hrow
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
Medium
Report
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
11/12
07:00 am
hrow
Harrow Announces Market Access Wins for VEVYE®
Medium
Report
Harrow Announces Market Access Wins for VEVYE®
11/7
07:00 am
hrow
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
Medium
Report
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
10/31
07:00 am
hrow
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
Low
Report
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
10/10
07:00 am
hrow
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Medium
Report
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
10/4
12:46 pm
hrow
Harrow, Inc. (NASDAQ: HROW) had its price target raised by analysts at Lake Street Capital from $45.00 to $55.00. They now have a "buy" rating on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) had its price target raised by analysts at Lake Street Capital from $45.00 to $55.00. They now have a "buy" rating on the stock.
10/4
09:54 am
hrow
Harrow, Inc. (NASDAQ: HROW) had its price target raised by analysts at Craig Hallum from $45.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) had its price target raised by analysts at Craig Hallum from $45.00 to $65.00. They now have a "buy" rating on the stock.
10/3
07:00 am
hrow
Harrow Relaunches TRIESENCE®
Medium
Report
Harrow Relaunches TRIESENCE®
9/25
12:02 pm
hrow
Harrow Announces Nashville Expansion
Low
Report
Harrow Announces Nashville Expansion
9/3
07:00 am
hrow
Harrow to Present at Three Investor Conferences in September in New York
Low
Report
Harrow to Present at Three Investor Conferences in September in New York
8/29
10:32 am
hrow
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $50.00 price target on the stock.
Medium
Report
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $50.00 price target on the stock.